BioMarin Pharmaceutical Inc.
NASDAQ:BMRNBiotechnology
-$0.10 today
- Market cap
- $11.90B
- Beta
- 0.24
- P/E (TTM)
- 39.4
- EPS (TTM)
- $1.40
Volume 3.07M
Average 2.04M
BMRN Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
BioMarin Pharmaceutical Inc.NASDAQ: BMRN
Revenue · Q3 FY2026 · quarter ended Sep 2026
Revenue growth accelerates
Q3 FY2026 revenue of $1.02T rose 131919.4% year over year, ahead of the +33102.2% change in trailing-twelve-month revenue. Sequentially, it rose 103430.1% from the prior quarter. Over 3 fiscal years it compounded at +15.4% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 20 analysts of $3.87B (+20.1%) for the fiscal year ending Dec 2026, a step up from the +12.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $1.02T+103430.1% QoQ
- Last fiscal yearDec 2025
- $3.22B+12.9% YoY
- LTMSep 2026
- $1.03T+33102.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +131919.4% | +24.5% | -131894.8 pp |
| 1 year | +12.9% | +20.1% | +7.2 pp |
| 3-year CAGR | +15.4% | +14.5% | -0.9 pp |
| 5-year CAGR | +11.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 3.22B USD
- Year-over-year change
- +12.9%
- 4-year CAGR
- +14.9%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.22B | +12.9% |
| FY2024 | 2024-12-31 | 2.85B | +18.0% |
| FY2023 | 2023-12-31 | 2.42B | +15.4% |
| FY2022 | 2022-12-31 | 2.1B | +13.5% |
| FY2021 | 2021-12-31 | 1.85B | — |
Revenue vs competitors
How BMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +33102.2% is the highest of 11, against a peer median of +32.3%.
- Over three fiscal years its annual growth of +15.4% compares with a peer median of +35.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $1.03T USD | +33102.2% | +15.4% | |
| LTM Sep 2026 | $12.99B USD | +10.8% | +10.6% | |
| LTM Jun 2026 | $4.8B USD | +95.1% | +53.0% | |
| LTM Sep 2026 | €1.21B EUR | +86.9% | +138.2% | |
| LTM Jun 2026 | $1.14B USD | +185.8% | +35.2% | |
| LTM Jun 2026 | $1.01B USD | -42.8% | +35.3% | |
| LTM Sep 2026 | $959.76M USD | -0.7% | +17.1% | |
| LTM Jun 2026 | $713.07M USD | +202.4% | +86.3% | |
| LTM Mar 2026 | $669.43M USD | +13.3% | +22.8% | |
| LTM Sep 2026 | $651.04M USD | +49.4% | +64.9% | |
| LTM Mar 2026 | $369.38M USD | +15.2% | +22.4% | |
| Peer median (excluding BMRN) | — | +32.3% | +35.3% | |
Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.85B | 2.1B | 2.42B | 2.85B | 3.22B |
| Cost of Revenue | 470.52M | 503.02M | 532.06M | 580.24M | 736.83M |
| Gross Profit | 1.38B | 1.59B | 1.89B | 2.27B | 2.48B |
| Gross Margin | 74.5% | 76.0% | 78.0% | 79.7% | 77.1% |
| Research & Development | 628.79M | 649.61M | 746.77M | 747.18M | 921.93M |
| Selling, General & Admin | 759.4M | 823.2M | 892.4M | 1.01B | 1.28B |
| Operating Expenses | 1.46B | 1.43B | 1.7B | 1.79B | 1.95B |
| Depreciation & Amortization | 108.04M | 101.97M | 104.39M | 96.43M | 79.56M |
| EBITDA | 47.43M | 265.36M | 306.77M | 650.53M | 572.94M |
| EBITDA Margin | 2.6% | 12.7% | 12.7% | 22.8% | 17.8% |
| Operating Income | (82.34M) | 160.97M | 185.77M | 484.21M | 533.48M |
| Operating Margin | -4.5% | 7.7% | 7.7% | 17.0% | 16.6% |
| Interest Income | 10.48M | 18.03M | 58.34M | 74.88M | 74.9M |
| Interest Expense | 15.34M | 15.97M | 17.34M | 12.67M | 10.9M |
| Other Income / Expenses | 6.99M | (11.4M) | 2.79M | 57.55M | (51M) |
| Income Before Tax | (75.35M) | 149.58M | 188.56M | 541.76M | 482.48M |
| Pre-Tax Margin | -4.1% | 7.1% | 7.8% | 19.0% | 15.0% |
| Income Tax Expense | (11.27M) | 8.02M | 20.92M | 114.9M | 133.58M |
| Net Income | (64.08M) | 141.56M | 167.65M | 426.86M | 348.9M |
| Net Margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| EPS (Basic) | (0.35) | 0.76 | 0.89 | 2.25 | 1.82 |
| EPS (Diluted) | (0.35) | 0.75 | 0.88 | 2.21 | 1.80 |
| Weighted Avg Shares | 182.85M | 185.27M | 187.83M | 190.03M | 191.79M |
| Weighted Avg Shares (Diluted) | 182.85M | 188.96M | 191.6M | 196.71M | 197.39M |
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
Intrinsic Alpha fair value
Locked
Current Price
$61.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.